Skip to main content

Table 1 Clinical characteristics of donor and mutation load in the 5 PDOs

From: Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment

 

CRC-01

CRC-03

CRC-04

CRC-05

CRC-08

Age at biopsy (years)

60

61

59

52

51

Sex

male

female

female

male

male

Stage

IV

IV

IV

IV

IV

Prior chemotherapy

Yes

Yes

Yes

Yes

No

Non-silent mutation load

208

106

89

180

78

APC

p.Y935X, p.S1411 fs

p.R876X

p.S1356X

p.Q1367X

p.Y1075fs

TP53

 

p.G245S

p.T284 fs

p.R210X

p.R205C

KRAS

p.G12C

Amplification

p.A18D

p.G12D

p.G12D

TCF7L2

 

p.F105 fs

   

SMAD4

  

p.G365R